News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
New and experimental HIV treatments
ViiV announces halt to lersivirine development

On February 5, 2013, ViiV Healthcare announced that the company has decided to stop the development program investigating its experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) lersivirine.

Published
07 February 2013
From
HIVandHepatitis.com
Pharmaceutical industry
Gilead racks up 18% sales hike as HIV meds keep growing

Gilead Sciences posted an impressive 18% growth in fourth-quarter revenues, to a street-beating $2.59 billion. Sales grew even in Europe, where austerity measures have been eating pharma's lunch. Profits beat estimates, too.

Published
06 February 2013
From
FiercePharma
New and experimental hepatitis C treatment
Idenix to Discontinue Development of Two Hepatitis C Treatments

Idenix Pharmaceuticals today announced the Company has elected not to continue its clinical development program for IDX184, a nucleotide polymerase inhibitor in phase IIb testing for the treatment of hepatitis C virus (HCV) infection, or to continue its development of IDX19368, an HCV nucleotide polymerase inhibitor for which the Company had previously filed an IND but had not initiated patient dosing.

Published
05 February 2013
From
Idenix press release
Pharmaceutical industry
Vertex hepatitis C drug revenues plummet

Vertex Pharmaceuticals (Nasdaq: VRTX) saw sales of its hepatitis C drug, Incivek, drop off precipitously in the fourth quarter, year over year. The fast decline in Incivek sales, less than two years after its U.S. Food and Drug Administration approval.

Published
30 January 2013
From
Boston Business Journal (blog)
New and experimental hepatitis C treatment
Phase II all-oral combination studies of simeprevir, TMC647055 and IDX719 for the treatment of hepatitis C to be initiated shortly

The collaboration will evaluate combinations including simeprevir (TMC435), a once-daily protease inhibitor jointly developed by Janssen R&D Ireland and Medivir, TMC647055, a potent once daily NNI (non-nucleoside inhibitor) of the HCV polymerase, boosted with low dose ritonavir, being developed by Janssen and IDX719, Idenix’s once-daily pan-genotypic NS5A inhibitor.

Published
29 January 2013
From
Medivir press release
New and experimental HIV treatments
Gilead Initiates Phase 3 Clinical Program for Tenofovir Alafenamide, a Novel Low-Dose Prodrug for the Treatment of HIV

The Phase 3 studies will examine a once-daily single tablet regimen of TAF 10 mg/elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg compared to Gilead’s Stribild®(elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) among patients new to HIV therapy.

Published
25 January 2013
From
Gilead press release
Pharmaceutical industry
Gilead petitions FDA over its Stribild AIDS med

In a challenge to FDA decisionmaking that will be closely watched by the pharmaceutical industry, Gilead Sciences has asked the agency to grant five years of exclusivity to its recently approved Stribild AIDS medication.

Published
25 January 2013
From
Pharmalot
Pharmaceutical industry
US finds sharp rise in ‘pay-for-delay’ deals blocking generics

he United States Federal Trade Commission, which keeps an eye out for anticompetitive behaviour, has issued a study finding that in 2012, a record number of deals were struck between brand-name and generic drug companies to keep the lower-priced generics off the market. Such deals, which arise from patent disputes, cost American consumers billions of dollars annually while piling on the federal deficit, it said.

Published
21 January 2013
From
Intellectual Property Watch
Pharmaceutical industry
Médecins Sans Frontières addresses study by Massachusetts General Hospital on implications of switching from branded to generic antiretrovirals for HIV

The just-released study stating that switching patients from the branded combination antiretroviral ‘Atripla’ to generics could be therapeutically ‘less effective’ is misleading and misses a big part of the picture. The harmful role played by patents in blocking the use of quality-assured generic combination drugs is overlooked. The article further conflates evidence that single-pill "fixed-dose combination" HIV drugs lead to better treatment outcomes with the false notion that generic medicines themselves may lead to worse outcomes.

Published
17 January 2013
From
MSF / EATG
Finance and funding
Study questions generic HIV drug use

Using generic HIV drugs could save the US health system $42,500 (£26,500) patients. A modelling study found that if the most pessimistic assumptions about generic drugs' effectiveness were used, this might be at the expense of 4.4 months of life lost, however.

Published
15 January 2013
From
BBC Health
← Prev12345...50Next →

Filter by country